Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables
Authors
Keywords
-
Journal
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
Volume 23, Issue 1, Pages 3-12
Publisher
SAGE Publications
Online
2017-08-22
DOI
10.1177/1074248417724868
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease
- (2017) Die Hu et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Hypertriglyceridaemia and risk of coronary artery disease
- (2017) Željko Reiner Nature Reviews Cardiology
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia
- (2017) Michael J. Koren et al. JAMA Cardiology
- Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms
- (2016) Amirhossein Sahebkar et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
- (2016) Josefa Girona et al. Cardiovascular Diabetology
- Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
- (2016) Robert S. Rosenson et al. CARDIOVASCULAR DRUGS AND THERAPY
- Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
- (2016) Hagai Tavori et al. CARDIOVASCULAR RESEARCH
- Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
- (2016) Giuseppe Danilo Norata et al. CARDIOVASCULAR RESEARCH
- Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
- (2016) Vera Bittner CIRCULATION
- Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective
- (2016) Gissette Reyes-Soffer et al. CIRCULATION
- Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismClinical Perspective
- (2016) Gerald F. Watts et al. CIRCULATION
- Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations
- (2016) Hayato Tada et al. CIRCULATION JOURNAL
- PCSK9 and Lipoprotein(a)
- (2016) Peter P. Toth CIRCULATION RESEARCH
- Sortilin: A novel regulator in lipid metabolism and atherogenesis
- (2016) Li-yuan Zhong et al. CLINICA CHIMICA ACTA
- Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
- (2016) Michel Farnier et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease
- (2016) Tsuyoshi Nozue et al. Journal of Atherosclerosis and Thrombosis
- Evaluating The Roles Of PCSK9 And Specific Receptors In Lipoprotein(A) Catabolism
- (2016) Marlys Koschinsky et al. Journal of Clinical Lipidology
- PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role
- (2016) Frederick J. Raal et al. JOURNAL OF LIPID RESEARCH
- Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo
- (2016) Peter P. Toth et al. Lipids in Health and Disease
- Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
- (2016) Tsuyoshi Nozue et al. Lipids in Health and Disease
- Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence
- (2016) Nicola Ferri et al. Translational Research
- Pharmacological management of diabetic dyslipidemia
- (2016) T. D. Filippatos et al. Expert Review of Clinical Pharmacology
- Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese
- (2016) S.-H. Yang et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population
- (2016) Pia R. Kamstrup et al. JACC-Heart Failure
- PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance
- (2015) Annie Demers et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal ObesitySignificance
- (2015) Jan Borén et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
- (2015) Xin-Lin Zhang et al. BMC Medicine
- Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state
- (2015) Dick C. Chan et al. CLINICAL SCIENCE
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients
- (2015) Ymène Nekaies et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials
- (2015) C. Li et al. Journal of the American Heart Association
- Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study
- (2015) Danish Saleheen et al. Lancet Diabetes & Endocrinology
- PCSK9 levels in abdominally obese men: Association with cardiometabolic risk profile and effects of a one-year lifestyle modification program
- (2014) Benoit J. Arsenault et al. ATHEROSCLEROSIS
- Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
- (2014) H. Abujrad et al. ATHEROSCLEROSIS
- The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion
- (2014) Camilla Gustafsen et al. Cell Metabolism
- Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
- (2014) Shirya Rashid et al. CIRCULATION
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Plasma proprotein convertase subtilisin–kexin type 9 is predominantly related to intermediate density lipoproteins
- (2014) Arjan J. Kwakernaak et al. CLINICAL BIOCHEMISTRY
- Latest developments in the treatment of lipoprotein (a)
- (2014) Sven Bos et al. CURRENT OPINION IN LIPIDOLOGY
- Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
- (2014) Rui-Xia Xu et al. Lipids in Health and Disease
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
- (2014) Anand Rohatgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study
- (2013) Theodosios D. Filippatos et al. Archives of Medical Science
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2
- (2013) Martijn C. G. J. Brouwers et al. CLINICAL SCIENCE
- High-Sensitivity C-Reactive Protein and Cardiovascular Disease
- (2013) Omair Yousuf et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Small High-Density Lipoprotein (HDL) Subclasses are Increased with Decreased Activity of HDL-Associated Phospholipase A2 in Subjects with Prediabetes
- (2013) Theodosios D. Filippatos et al. LIPIDS
- Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9
- (2013) Seungbum Choi et al. Lipids in Health and Disease
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
- (2013) Maryssa Canuel et al. PLoS One
- Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study
- (2013) TD Filippatos et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
- (2013) Rose Q. Do et al. Current Cardiology Reports
- Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
- (2012) Arjan J. Kwakernaak et al. ATHEROSCLEROSIS
- A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
- (2012) Theodosios D. Filippatos CARDIOVASCULAR DRUGS AND THERAPY
- A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
- (2012) Anastazia A. Kei et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
- (2011) Anna Roubtsova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia
- (2011) Aris P Agouridis et al. EXPERT OPINION ON PHARMACOTHERAPY
- High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n-3 Fatty Acids in Mixed Dyslipidemia
- (2011) A. P. Agouridis et al. LIPIDS
- Leptospirosis is Associated with Markedly Increased Triglycerides and Small Dense Low-Density Lipoprotein and Decreased High-Density Lipoprotein
- (2011) Irene F. Gazi et al. LIPIDS
- The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations
- (2011) Lynn Htet Htet Aung et al. Lipids in Health and Disease
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
- (2011) Amit V. Khera et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination of Fenofibrate with Non-Statin Drug Regimens
- (2010) A. P. Agouridis et al. CURRENT PHARMACEUTICAL DESIGN
- Review Article: Effects of Plant Sterols and Stanols Beyond Low-Density Lipoprotein Cholesterol Lowering
- (2010) Christos S. Derdemezis et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
- (2010) Renata Belfort et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Plasma triglyceride levels and body mass index values are the most important determinants of preβ-1 HDL concentrations in patients with various types of primary dyslipidemia
- (2009) Vasilis Tsimihodimos et al. ATHEROSCLEROSIS
- Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents
- (2009) A. Baass et al. CLINICAL CHEMISTRY
- Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors
- (2009) TD Filippatos et al. Clinical Lipidology
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
- (2009) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia
- (2009) Michael S. Kostapanos et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of hormonal treatment on lipids in patients with cancer
- (2008) T.D. Filippatos et al. CANCER TREATMENT REVIEWS
- Treatment of hyperlipidaemia with fenofibrate and related fibrates
- (2008) Theodosios Filippatos et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia
- (2008) ES Nakou et al. EXPERT OPINION ON PHARMACOTHERAPY
- Chylomicron remnants are increased in the postprandial state in CD36 deficiency
- (2008) Daisaku Masuda et al. JOURNAL OF LIPID RESEARCH
- Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome
- (2008) K. G. Lagos et al. LIPIDS
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome
- (2007) T. D. Filippatos et al. DIABETES OBESITY & METABOLISM
- Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women
- (2007) T. Tzotzas et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started